Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib
暂无分享,去创建一个
[1] Shing M. Lee,et al. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Novotny,et al. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. , 2016, The Lancet. Oncology.
[3] M. Dimopoulos,et al. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study , 2015, American journal of hematology.
[4] I. Tannock,et al. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Schilsky,et al. Optimizing Dosing of Oncology Drugs , 2014, Clinical pharmacology and therapeutics.
[6] L. Collette,et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo , 2014, European journal of cancer.
[7] Tiffany Shao,et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Xavier Paoletti,et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Dimopoulos,et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Gandara,et al. Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339) , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[12] D. Gandara,et al. The Proteasome Inhibitor Bortezomib in Combination with Gemcitabine and Carboplatin in Advanced Non-small Cell Lung Cancer: A California Cancer Consortium Phase I Study , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] J. Crowley,et al. Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] S. Soignet,et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.